187 related articles for article (PubMed ID: 37234285)
1. Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors.
Deken MA; Niewola-Staszkowska K; Peyruchaud O; Mikulčić N; Antolić M; Shah P; Cheasty A; Tagliavini A; Nizzardo A; Pergher M; Ziviani L; Milleri S; Pickering C; Lahn M; van der Veen L; Di Conza G; Johnson Z
Immunooncol Technol; 2023 Jun; 18():100384. PubMed ID: 37234285
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models.
Centonze M; Di Conza G; Lahn M; Fabregat I; Dituri F; Gigante I; Serino G; Scialpi R; Carrieri L; Negro R; Pizzuto E; Giannelli G
J Exp Clin Cancer Res; 2023 Aug; 42(1):197. PubMed ID: 37550785
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin Inhibition with IOA-289 Decreases Breast Tumor Growth in Mice Whereas Knockout of Autotaxin in Adipocytes Does Not.
Tang X; Morris AJ; Deken MA; Brindley DN
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296899
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Characterization, and
Hunziker D; Reinehr S; Palmhof M; Wagner N; Biniasch T; Stute G; Mattei P; Schmitz P; DiGiorgio P; Hert J; Rudolph MG; Benz J; Stihle M; Gsell B; Müller S; Gasser R; Schonhoven N; Ullmer C; Joachim SC
Front Pharmacol; 2021; 12():699535. PubMed ID: 35126098
[TBL] [Abstract][Full Text] [Related]
5. Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer.
She S; Zhang Q; Shi J; Yang F; Dai K
Front Oncol; 2022; 12():922945. PubMed ID: 35769713
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
7. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
8. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Farquhar MJ; Humphreys IS; Rudge SA; Wilson GK; Bhattacharya B; Ciaccia M; Hu K; Zhang Q; Mailly L; Reynolds GM; Ashcroft M; Balfe P; Baumert TF; Roessler S; Wakelam MJO; McKeating JA
J Hepatol; 2017 May; 66(5):919-929. PubMed ID: 28126468
[TBL] [Abstract][Full Text] [Related]
12. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A
BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518
[TBL] [Abstract][Full Text] [Related]
13. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer.
Kaffe E; Magkrioti C; Aidinis V
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652837
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface.
Peyruchaud O; Saier L; Leblanc R
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906151
[TBL] [Abstract][Full Text] [Related]
15. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
Trovato FM; Zia R; Napoli S; Wolfer K; Huang X; Morgan PE; Husbyn H; Elgosbi M; Lucangeli M; Miquel R; Wilson I; Heaton ND; Heneghan MA; Auzinger G; Antoniades CG; Wendon JA; Patel VC; Coen M; Triantafyllou E; McPhail MJ
Hepatology; 2021 Aug; 74(2):907-925. PubMed ID: 33908067
[TBL] [Abstract][Full Text] [Related]
17.
Wang S; Chen J; Guo XZ
World J Gastrointest Oncol; 2022 Aug; 14(8):1388-1405. PubMed ID: 36160748
[TBL] [Abstract][Full Text] [Related]
18. Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease.
Flores-López M; García-Marchena N; Pavon FJ; Lara E; Porras-Perales O; Araos P; Requena-Ocaña N; Torres-Galván S; Mañas-Padilla MC; Rubio G; Suárez J; Santín LJ; Rodríguez de Fonseca F; Castilla-Ortega E; García-Fernández MI; Serrano A
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572393
[TBL] [Abstract][Full Text] [Related]
19. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
20. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
